After reviewing the results of 23 studies based on TNF therapy, this systematic review showed that TLR2 variants (such as rs3804099 and rs1816702) in IBD patients are promising markers for the prediction of response to anti‐TNF therapy response. This evidence concerns the gene TNF and inflammatory bowel disease.